BioCentury
ARTICLE | Financial News

Third Rock backs Fulcrum in $55M series A

July 19, 2016 7:00 AM UTC

Third Rock Ventures launched Fulcrum Therapeutics Inc. (Cambridge, Mass.) and was the sole investor in the gene control company's $55 million series A financing. Fulcrum is developing small molecules that modulate targets responsible for regulating genes. Initially, the company has discovery-stage programs for two genetic diseases: fragile X syndrome and facioscapulohumeral muscular dystrophy.

Fulcrum also named Robert Gould as president and CEO. He was president and CEO of Epizyme Inc. (NASDAQ:EPZM), which develops epigenetic therapies for cancer. ...